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The substance that empowers? DNA in South Asia.   
 
Abstract: Drawing on two ethnographic examples of the socio-cultural 
aspects of populations genetic research in India, the paper explores in what ways 
tests aimed at assessing ‘genetic differences’ between populations can be viewed 
as enabling or disempowering for individuals, communities or nations subjected 
to such tests. The first one builds on a response to DNA research demonstrated 
by the leaders of the Jewish Bene Ephraim community of Andhra Pradesh, a Dalit 
group who in the late 1980s declared their descent from the Lost Tribes of Israel. 
The second focuses on the Indian Genome Variation Consortium, a research 
network established in India in 2003 with the aim of mapping the country’s 
human genetic diversity. Building upon Prainsack and Toom’s theoretical 
concept of situated dis/empowerment, I suggest that in both case studies 
empowering and disempowering elements of DNA testing appear to co-
constitute and co-produce each other, as they both reinforce reductionist 
accounts of human sociality and serve as rhetorical tools for social and political 
liberation.  
 
Key words: population genetics, India, Dalits, Bene Ephraim, genomic 
sovereignty.  
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Aihwa Ong has observed in her Introduction to Asian Biotech that in Asia 
‘biotechnologies are allied to nationalist efforts to overcome past humiliations 
and to restore national identity and political ambition’ (Ong 2010: 3). Writing 
specifically about the subcontinent, Kaushik Sunder Rajan has argued that India 
has been prioritising the development of science and technology as a way of 
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becoming a power to reckon with in the international arena. In the process of 
developing its involvement in the life sciences and biotechnology it has both 
displayed characteristics of a ‘colonised’ state actor and has framed itself as a 
‘global player’ in biotech, he suggests (2006).   
In this paper I would like to use ethnographic examples taken from two 
different cases in my research on the socio-cultural significance of population 
genetics to explore how the politics of science research has played out in the 
context of DNA studies, and in what ways tests aimed at assessing ‘genetic 
differences’ between populations can be viewed as enabling or disempowering 
for individuals, communities or nations subjected to such tests. The two case 
studies that I will use in this discussion are very different in scale. The first one 
builds on a response to DNA research demonstrated by the leaders of the Jewish 
Bene Ephraim community of Andhra Pradesh, a Dalit group who in the late 
1980s declared their descent from the Lost Tribes of Israel.1 The second focuses 
on a study aimed at categorizing and reconstructing the history of South Asian 
populations.  In both cases I will discuss to what extent and in what ways DNA 
research engages with the agendas of those who solicit them – the Bene Ephraim 
leaders in the first case and Indian authorities in the second. What kind of data 
are DNA tests expected to yield and what meanings do different actants ascribe 
to these data? How is agency distributed in identification practices involving 
DNA collection? Do genetic tests leave any room for a rhetorical reinterpretation 
of the produced findings?  
Reflecting on the role that genetics has played in projects aimed at 
reconstructing collective and individual pasts, the historian of science Marianne 
Sommer has observed that ‘We have only just begun to understand the complex 
processes at work when DNA technologies enter into cultures of remembrance. 
Nonetheless, our current knowledge points towards the importance of the 
history and diversity of these cultures for the ways in which communities may or 
may not come to (re) imagine themselves in terms of new genetically based 
histories and in relation to biosocialities, which may or may not (re) form around 
genetic markers of ancestry’ (2010: 387). This paper will use the case studies 
mentioned above to continue the discussion, which has been on-going in the 
social studies of science about the potential socio-cultural and political 
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consequences of population genetic research concerned with reconstructing 
human histories. It has been widely noted that, on the one hand, DNA research, 
which builds upon notions of biological determinism, has an unavoidable 
tendency to naturalise and therefore reinforce existing categories of people 
based on perceived genealogical and social differences (Abu El-Haj 2007, Duster 
2005, Palmie 2007, Palsson 2007, Reardon 2005, Simpson 2000, Skinner 2006, 
Smart et al 2008). DNA has thus often been described as a substance that 
reinstates biological notions of personhood, and genetic anthropology appears to 
be, as Sommer has put it,  ‘part of backward-looking socialities’ (2010: 370).  
At the same time, it has also been shown that though ‘DNA evidence’ is 
widely deployed as a rhetorical means for inscribing identities, it is often used 
selectively to support favoured accounts about the origin and historical 
development of different groups (Nelson 2008, Egorova 2009a, Egorova 2009b, 
Prainsack and Hashiloni Dolev 2009). In this paper I would like to take this 
discussion in a congruous yet somewhat different direction, and explore the 
complex roles that ‘DNA substance’ has emerged to play in the ‘tissue economies’ 
(Waldby and Mitchell 2006) of contemporary India. In the first case study I will 
examine how, in an attempt to prove their Jewish origin to outsiders, the 
community of the Bene Ephraim have tried to use ‘DNA evidence’ as a source of 
identity arbitration. I will argue that though community leaders seem to 
recognize the reductionist agenda of DNA research, they also see it as a potent 
rhetorical weapon to use against those who have raised doubts about their 
Jewishness, and as a last resort to prove their origin narrative. In their case, DNA 
thus emerges both as a vehicle for transmitting a time-old naturalizing discourse 
of ‘Jewish difference’, and as a new, subaltern, means for social empowerment.   
My second case considers research aimed at creating a genetic map of 
Indian populations. It will be shown that one of the meta-objectives of studies in 
human genetic variation of the subcontinent has been to facilitate India’s 
emergence as a market actor in the realm of global bionetworking by making 
local populations more ‘accessible’ for clinical trials conducted for multinational 
clinical companies. Just as the leaders of the Bene Ephraim feel that they need to 
subject their community to a novel biotechnological practice to secure their 
place among other Jewish groups around the world, Indian authorities are ready 
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to offer the ‘merely risked’ (Sunder Rajan 2010) bodies of their citizens to 
establish their position as a serious player on the international arena of global 
science.  
In discussing the two cases I will rely on interviews conducted with the 
leaders of the Bene Ephraim in 2009 and 2010 and with ten scientists working in 
the field of population genetics, conducted from 2008 to 2010. In the second case 
study my discussion will also be based on an analysis of five articles presenting 
the rationale and findings of the Indian Genome Variation Consortium, a 
research network established in India in 2003 with the aim of mapping the 
country’s human genetic diversity. In this respect I will be referring to interviews 
with IGVC scientists presented in these articles.  
The paper will explore in this respect to what extent participation in 
contemporary practices of the life sciences and biotechnology possesses the 
potential to enable or disempower the tested, to ‘overcome past humiliations’ 
(Ong 2010: 3), or to surrender ambitions of sovereignty and autonomous notions 
of relationality. I will use in my discussion the concept of ‘situated 
dis/empowerment’, introduced by Barbara Prainsack and Victor Toom in the 
context of their research on surveillance and then further developed by 
Prainsack and Machado in their study of prisoner’s views of DNA technologies 
(2012). This concept highlights the ‘simultaneity of both empowering and 
oppressive effects’ of this practice (2010: 102), drawing attention to the way the 
oppressive and enabling elements of technology are co-produced. Similarly, in 
this paper I will explore examples in which ‘DNA evidence’ empowers tested 
communities in some contexts while disempowering them in others, and will 
argue against a ‘one-size-fits all’ account about the role that DNA techniques play 
in matters of agency and power distribution.  
 
Jewish DNA in India 
 
In June 2010 two papers appeared in major scientific journals  - Nature 
and the American Journal of Human Genetics – which attempted to address the 
question about the “genetic structure” of the Jewish people (Behar et al 2010; 
Atzmon et al 2010). Both papers set out to assess the degree of Jewish 
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communities’ “genetic” relatedness to each other and to their non-Jewish 
neighbours, and to explore whether the origin of contemporary Jews could be 
traced to the Middle East. 
The two articles contribute to a sizeable body of genetic research that 
has endeavoured in one way or another to test the account of Jewish history, 
according to which contemporary Jews are genealogically connected to ‘ancient 
Hebrews’.2 Both in their interviews with me and in the mass media geneticists 
involved in such studies have warned against using genetics as a means of 
identifying either an individual or a community as Jewish or non-Jewish.3 They 
appeared to perceive and describe this kind of genetic study as nothing more 
than a new tool for historical work that was already taking place. The 
researchers were adamant that being Jewish could not be reduced to DNA and 
argued that their work aimed at providing additional evidence to tackle a riddle 
of history, which otherwise could not be solved by using conventional historical 
tools. Every scientist stressed in the interviews that being Jewish had nothing to 
do with genetics and that Judaism should not be understood as a religion 
centered around a particular ethnicity. Many respondents emphasized that it 
was possible to convert to Judaism and acknowledged that not every person who 
considered himself or herself to be Jewish and came from a well-established 
Jewish community would have a genetic connection to the Levant.  
As I have demonstrated elsewhere, genetic studies do not always reach a 
consensus about the way Jewish populations were founded (Egorova 2009a: 
171-172). More importantly, so far professional historians have engaged with 
genetic research only to a very limited degree and normally refrain from using 
the findings of genetic anthropology as historical evidence (Egorova 2010a). 
And yet, it appears that in some quarters the biologisation of Jewish 
history effected by genetics will unavoidably create the perception that DNA 
could be used as a much more potent, if not critical, marker of identification. An 
interesting example of this became evident during my ethnographic research on 
the Bene Ephraim of Andhra Pradesh (India).4  
The community of the Bene Ephraim was established in the late 1980s in 
the village of Chebrole of Guntur District of Andhra Pradesh by a group of 
Christianised Madiga Dalits (untouchables) who declared that they belonged to 
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the Lost Tribes of Israel.5 The group is led by two brothers who adopted the 
names of Shmuel and Sadok Yacobi. In 1991 they established a synagogue and 
introduced a number of Jewish rites into the practice of their congregation.  At 
the moment, the Bene Ephraim number about one hundred and fifty people who 
are in one way or another associated with the community and are willing to 
emigrate to the State of Israel. In their everyday life community members strive 
to observe Jewish dietary laws, rules of circumcision, the Sabbath and the main 
Jewish holidays.  
In 2002 Shmuel Yacobi published a book entitled The Cultural 
Hermeneutics, offering an account of the history of the community, which may be 
summarized as follows. The Bene Ephraim descended from the tribes of Israel, 
who in 722 BCE were exiled from the ancient kingdom of Israel by the Assyrians. 
After their sojourn in Persia, they moved to the northern part of the 
subcontinent, which was then populated by Dravidian groups. In the seventh 
century BCE, the subcontinent was conquered by the ‘Aryans’, who established 
the caste system and relegated the Dravidians and the Bene Ephraim to the 
positions of Shudras and untouchables respectively. Both groups were later 
forcibly relocated to the south of India, where they now reside. The current state 
of affairs in the community is explained as an unfortunate result of the further 
advance of ‘Aryan rule’, under which the Bene Ephraim lost their status and 
political significance, were reduced to poverty and, left with very few means of 
maintaining their tradition, almost forgot it entirely (Yacobi 2002). 
It appears from the accounts of the Yacobis and of their village 
neighbours that the community began practising Judaism openly only in the late 
1980s; however, the Yacobis maintain that their parents and grandparents had 
been aware of their Israelite origin and had practised Judaism in secret for a long 
time. The Judaisation of the Bene Ephraim has been dismissed by some 
commentators as an attempt by a former untouchable community to change its 
members’ position in the local hierarchy, or to improve their material 
circumstances by moving to the state of Israel. The Yacobis stress that their low-
caste status had nothing to do with the emergence of the Bene Ephraim. At the 
same time, Shmuel Yacobi concedes that his research and activism in respect of 
identifying the Israelite connection was partially driven by observing his fellow 
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members’ exploitation at the hands of higher castes. Embracing the Jewish 
tradition was his way to vocalize a protest against the social system that put his 
community at a disadvantage.  
Anthropologists and historians of Judaising movements have discussed a 
number of socially marginalized groups who, similarly to the Bene Ephraim, 
have reinterpreted their condition of discrimination in light of Jewish history. 
Some of them turned to Judaism because the historical experience of the 
suffering of the Jewish people seemed to mirror that of their own (Parfitt and 
Trevisan Semi 2002: viii). In the twentieth century a considerable number of 
Judaising movements emerged in different parts of Africa, as well as among 
African American groups. It has been demonstrated that for some of these 
groups, and particularly those that developed in the USA, embracing Judaism 
represented a protest against white supremacism and a search for new modes of 
self-understanding (Singer 2000, Markowitz et al 2003, Jackson 2005, Dorman 
2006, Bruder 2008). Interestingly, these attempts to establish a connection with 
a community who had similar experiences of discrimination resonate with the 
efforts of Dalit groups who equated caste discrimination with racism by arguing 
that the severity of their oppression in India is comparable to if not worse than 
that of Black communities in the West (for a detailed discussion see Reddy 
2005). 
The story of the Bene Ephraim suggests both a desire to express social 
protest and a need to explore the past. However, as I demonstrate below, it also 
illuminates the strength of the perception that membership in the Jewish 
community is based on Jewish genealogy and that in issues of Jewish identity 
arbitration ‘genetic evidence’ has the potential to give one’s claims a greater 
degree of cultural weight.  
Recently the leaders of the community suggested that the Bene Ephraim 
should undergo DNA tests to prove that they were Jewish.6 This understanding 
of the role of genetics appears to go well beyond the assertions of geneticists 
themselves, quoted above, that these studies are of general interest regarding 
ancestry and history, but are not applicable to individuals or communities for 
the purposes of identifying them as Jewish. Community leaders chose to 
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construe the Jewish people as a natural family and to use genetics to justify their 
place in it.  
The Bene Ephraim were not the first Jewish community to see genetics 
as a route to external recognition. The Bene Israel, another Indian Jewish group, 
paid a great deal of attention to the outcomes of a genetic study conducted 
among them, and were delighted when the results turned out to be ‘positive’ 
(Parfitt and Egorova 2006, Egorova 2009b).7 For both communities DNA 
identification becomes important in light of the fact that their early history is not 
well documented. Both the Bene Israel and the Bene Ephraim perceive DNA as a 
marker of identification that external agents are likely to recognise as valid.  
At the same time, it is noteworthy that both the Bene Israel and the 
Bene Ephraim have a strong sense of being Jewish irrespective of what their 
‘genetic profile’ (endorsed by Western science) may be. As Tudor Parfitt and I 
suggested elsewhere, the Bene Israel used the results of DNA research to affirm 
their Jewishness in the face of those who doubted their origin, but they made it 
clear that they were confident they were Jewish no matter what the tests would 
have indicated. Moreover, they reinterpreted these results in light of their own 
tradition as proving the community to be the ‘purest of the Jews’ (Parfitt and 
Egorova 2006). In the case of the Bene Ephraim, it appears that if a DNA study 
were to be carried out among them and its results proved to be negative, the 
community would be very unlikely to accept them. When I asked Sadok Yacobi 
about the possibility of genetic results turning to be negative, he replied that it 
was not possible, unless the geneticists were to make a mistake. 
Communities like the Bene Ephraim and the Bene Israel struggle to 
produce material artefacts documenting their early history and feel that the only 
evidence of Jewish origin that they can offer their interlocutors is their DNA. The 
interest that the Bene Ephraim have expressed in embracing genetic history 
indicates that while accepting its biological determinism, they also perceive it as 
imbued with liberatory potential and thus construct the ‘gene’ both as an 
immutable determinant of identification and as a site of agency and re-
signifiability. On the one hand, it forces the community to conform to a 
naturalistic, biologised account of Jewish history. On the other, it provides a 
novel and subaltern way of telling a story which cannot be convincingly told in 
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the absence of ‘conventional’ historical evidence.  
Like other Dalits, the Bene Ephraim lack written sources of their early 
history. Like other Judaising movements, they cannot produce documented 
evidence of their genealogical connection to the Jewish people. They therefore 
see DNA as the only existing testimony to their Jewish connection, the only 
document of their heritage that all ‘proper’ Bene Ephraim carry within their 
bodies, the only piece of evidence they can produce despite their poverty and 
low social status.  DNA is seen by community leaders as a substance that 
empowers, a trace of Jewishness which cannot be taken away from them. 
However, the question which remains to be asked is whether the perceived 
empowering elements of DNA testing  - should such tests be performed on the 
Bene Ephraim – would translate themselves into positive developments for the 
community ‘on the ground’ or whether they will remain in the imagination of its 
leaders. Would the assertions of the Bene Ephraim about their genetic 
relatedness to the rest of the Jewish people have weight in the eyes of Israeli 
authorities? How much agency could they exercise in facilitating their migration 
to the Jewish State with or without ‘genetic evidence’ if the State were to decide 
against this migration? Finally, what would happen if such tests were conducted 
and the results turned out to be ‘negative’? To return to Prainsack and Toom’s 
concept of situated dis/empowerment, in the case of the Bene Ephraim, ‘DNA 
evidence’ contains the promise and the danger of both. The practice of genetic 
history gives the community hope to be able one day to produce proof of their 
origin, but stands in the way of creating an alternative account of Jewish 
relatedness, an account which would not involve biogenetic genealogy.  
 
DNA ‘when experiments travel’8 
 
In this section our attention will turn to a study of a much larger scale – 
the Indian Genome Variation (IGV) Consortium Project set up in 2003 to run for 
five years.  The IGV is a research programme involving six laboratories of the 
Council of Scientific and Industrial Research, funded by the Government of 
India.9  As one of the more recent papers published on the basis of the IGVC 
research states, the aim of the IGV initiative was ‘to develop a database of 
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genomic variations in Indian population for predictive marker discovery in 
complex diseases’ (Narang et al 2010: 1). This and other publications stemming 
from the IGV Project stress that Indian populations offer a fertile ground for 
genetic studies of complex diseases. For instance, an article which appeared in 
the Journal of Genetics, published by the Indian Academy of Science, explains that 
‘Indians, comprising about one-sixth of the world population, with large family 
sizes and high levels of endogamy, provide a unique resource for dissecting 
complex disease etiology and pathogenesis’ (Indian Genome Variation 
Consortium 2008: 3).  The paper thus clearly construes Indian populations as a 
special biological resource, which is valuable because of the sheer numbers of 
people that it comprises, and the way these people are divided into castes. More 
specifically, the Project attempted to find out if the frequencies of SNPs10 
associated with complex diseases were similar across different populations in 
India, whether the clusters of populations which shared similar SNP frequencies 
correlated with ethnic, linguistic or geographic population groups in India, and 
whether it was possible to identify ‘at-risk’ populations for complex disorders, 
poor response to medication and predisposition to infectious diseases (Indian 
Genome Variation Consortium 2008: 4). In other words, were different 
categories of people in India prone to have different illnesses? Were people 
belonging to different ‘ethnic’ groups, speaking different languages, and living in 
different parts of the subcontinent going to differ on the level of biology?   
    Elsewhere I have discussed the socio-political context of studies in 
population genetics in India, and particularly, the time-old assumptions about 
the alleged ‘biological’ differences between Indian caste and linguistic groups 
that such studies appear to be based on (Egorova 2009a, Egorova 2010a).  Here I 
will focus on one aspect of population genetic mapping in India, which connects 
this research to international clinical trials conducted in South Asia. The main 
product of the IGV initiative has been a database of genomic diversity in Indian 
populations. The web-site of the IGV Project, as well as the papers produced by 
it, often stress the potential benefits of this research for medical care. Thus, the 
IGVC web-site notes that two of the Project’s objectives are to ‘discover 
informative SNPs, CNVs and repeats in over 1000 genes of biomedically 
important metabolic and genetic networks and also genes of pharmacogenetic 
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relevance’,11 and to ‘apply haplotype maps for disease association studies and 
pharmacogenomics’.12 An article reporting the results of the IGV Project 
introduces a long list of complex disorders that the study aimed to map 
genetically.  The paper states that  ‘the representative set of genes’ that the study 
explored ‘included drug-response genes, genes involved in cancer and aging, eye 
diseases, allergy and asthma, neuro-psychiatric, metabolic and cardiovascular 
disorders as well as genes involved in susceptibility to infections etc.’ (Indian 
Genome Variation Consortium 2008).         
Why did the scientists set an objective to explore how genes were 
involved in these multi-factorial conditions, and why did they need to know how 
exactly they were distributed in Indian populations? Who are the potential 
beneficiaries of this research? An article based on interviews with key 
representatives of the IGVC and published in Nature Reviews Genetics suggests 
that because of its large population and a high rate of infectious and chronic 
disease, India cannot afford Western-style models of health-care provision, and 
that therefore ‘[g]enomic sciences and related technologies can add value to 
India’s local health-care system by emphasizing prediction and prevention, and 
possibly decreasing the cost of health care through better diagnosis, early 
detection, and improved treatment and management’ (Hardy et al 2008: S9-S10). 
Such a predictive genetic database is thus aimed to help Indian authorities to 
improve the medical care of its population. The subjects who are supposed to be 
empowered by this research are first and foremost Indian citizens.   
At the same time, the article goes on to observe that the ‘key driver’ 
behind the initiative were economic benefits and that a predictive population 
genetic database would make India a more attractive locale for international 
clinical trials. As Hardy et al, who interviewed the Consortium’s scientists, note:  
 
‘Participants explained to us that emerging innovative genomic-based 
initiatives such as the IGV contribute towards scientific capacity 
building, developing and retaining valuable human resources, and 
providing Indian scientists and the growing domestic private sector with 
a competitive edge on the global market. In a step towards this last goal, 
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members of the IGV have proposed developing a predictive population 
therapy database’ (Hardy et al 2008: S10).  
 
DNA research is clearly portrayed here as a tool for national 
empowerment – it is bound to build capacities and develop human resources of 
Indian science. Putting human genetic diversity on the map of India is supposed 
to result in putting India on the global map of cutting-edge research. But simple 
mapping is not the final goal of this endeavor - the mapping exercise has to lead 
to the development of a ‘predictive population therapy database’. As IGVC 
representatives explained to the same author (quoted above), the advantage of 
using genomic sciences in the context of the Indian health care system, which 
‘cannot afford Western-style models of health-care provision,’ is that it allows to 
‘predict and prevent’ disease and can thus be expected to reduce the costs of 
health care. Let us leave for the moment the question about whether this 
approach to treatment will indeed result in cheaper and more effective 
treatment, and consider how Hardy’s respondents further conceptualise  the 
deployment of such a database in India. Surprisingly, having first stated that the 
IGV initiative was going to ‘contribute towards scientific capacity building’, and  
‘developing and retaining valuable human resources’, the article goes on to 
observe that a predictive population genetic database would make India a more 
attractive locale for international clinical trials: 
 
‘The database, either solely using IGV data or potentially in combination 
with additional clinical data, would enable various clients to select 
clinical trial participants in order to stratify clinical trials.  Multinationals 
have been increasingly conducting early stage clinical trials in India 
because of the cost savings and readily accessible, largely drug-naive 
population resource. India has thus positioned itself as a global hub for 
conducting clinical trial research by investing in capacity and 
infrastructure. Some domestic companies subsidize their research and 
development (R&D) platforms by providing contract services for clinical 
trials for multinational and foreign companies. Accordingly, a ‘predictive 
population database’ could help maintain India’s competitive edge by 
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improving the selection specificity through stratification of the test 
population, thereby further reducing the time and cost associated with 
conducting clinical trials in India (Hardy et al 2008: S10). 
 
This passage suggests that what is at stake in the development of such a 
database, is not just India’s chances to improve the health care of her citizens, 
but also her ‘competitive edge’ in the conduct of clinical trials. What is the 
context of such trials and what role has India come to play in them?  
Clinical trials are carried out to establish the safety and efficacy of drugs 
and are now widely practiced in the developing world. Such experiments have in 
recent years developed from small scale localised experiments to complex trials 
involving thousands of people located in different countries (Simpson and 
Sariola 2012: 2). As Sunder Rajan has observed, various Indian actors, such as 
clinical research organisations (CROs),13 the pharmaceutical industry and 
various regulatory and educational agents envisage India as a major 
experimental site in international clinical trials and welcome more and more 
global clinical trial activity into the country (2010). Sunder Rajan’s study 
demonstrates that CROs are acutely aware of the importance of building up a 
positive image of such activities, and are adamant that high ethical standards 
should be maintained throughout the process. The story of clinical trials in India 
is thus much more complicated than that of Western entrepreneurs exploiting 
Indian populations, and requires analyzing the efforts that the Indian state itself 
makes to turn the country into a global experimental site. However, as Sunder 
Rajan has demonstrated, though Indian actors strive to surround clinical 
research with capacity-building initiatives and ethical safeguards, their efforts 
fail to mitigate the structural violence that clinical trials involve in Third World 
contexts, where due to structural inequalities, there are more ‘bioavailable’ 
(Cohen 2001, 2004) bodies ready to act as experimental subjects (Sunder Rajan 
2010).  Or, as Amit Prasad has discussed, while the people on whom drugs are 
tested give India an important advantage in the world market, they are very 
unlikely to benefit from the medications that will be developed following the 
trials. Moreover, due to the problems of Indian state healthcare, they hardly have 
proper access even to the drugs that are already available (Prasad: 2009: 4).     
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The predictive genetic database that the IGV consortium has produced is 
a critical example of an initiative in which a variety of Indian actors – scientists 
and managers of the IGVC, government officials, representatives of regulatory 
organisations – engage in promoting a piece of scientific research which both 
promises to secure India’s place among the key players on the global arena of 
biotechnology, and to use the ‘bioavailability’ of Indian subjects in a more 
efficient way. Indeed, as Hardy et al’s respondents suggested in the quote offered 
above, ‘a “predictive population database” could help maintain India’s 
competitive edge by improving the selection specificity through stratification of 
the test population, thereby further reducing the time and cost associated with 
conducting clinical trials in India’ (Hardy et al 2008: S10).  Initiatives such as the 
IGVC will indeed result in ‘developing and retaining valuable human resources’, 
only these will be human resources belonging to the ranks of scientists, while the 
human resources involved in clinical trials as test subjects will hardly have their 
skills, knowledge or well-being advanced.    
As I have argued elsewhere, this type of mapping exercises have been 
presented by their initiators as an effort to promote India’s ‘genomic 
sovereignty’ 14 that other, world-wide, mapping initiatives cannot provide 
(Egorova 2010b). Similarly, scientists and other stakeholders in the IGV 
Consortium endeavor to position Indian genomics as an equal partner in the 
international research arena, and to benefit and protect Indian patients. For 
instance, the hope was expressed that personalized genomic medicine will take 
off among Indian physicians due to their already existing familiarity with 
Ayurveda, a traditional form of personalized medicine, which is widely practiced 
across the country (Hardy et al 2008: S10). At the same time, there is the 
realization that protecting local health care interests will be a long and tortuous 
process. One of my informants suggested that tangible medical outcomes for 
Indian populations remain a long way away. Some of Hardy et al’s 
intervieweesinformants observed that there is no guarantee that Indian 
populations will receive any significant long-term economic or health-care 
benefits from this research at all (2008: S11). DNA testing is here called upon to 
enable the development of Indian science and technology at the expense of those 
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Indian citizens who become the ‘merely risked’ (Sunder Rajan 2010) victims of 
social inequalities and structural violence inherent in clinical trials.    
At the same time, we cannot ignore the fact that the posited value of the 
genetic mapping that the IGV initiative had set out to produce is still highly 
speculative and the promise of more efficient clinical trials is used by IGV 
representatives as a rhetorical tool which is called upon to present their research 
as a necessary step in the direction of enhancing India’s image of a serious player 
on the international arena of cutting-edge biotechnology research.15 No matter 
whether the genetic mapping exercise will indeed make the process of 
conducting clinical trials in India more expedient, the very rhetoric of clinical 
trials merged with the rhetoric of DNA research is constituted in the discourse of 
IGV participants as empowering.   
 
Conclusion 
 
To reflect on the wider implications of both case studies, it appears that 
DNA emerges here as a substance that dis/empowers. On the one hand, to build 
on Aihwa Ong’s arguments, biotechnology contains a promise of overcoming past 
humiliations. For the Bene Ephraim and the Bene Israel, it is the humiliations 
associated with not being recognized as a ‘bona fide’ Jewish community, and, in 
the case of the Bene Ephraim, humiliations associated with untouchability. 
Luckily for the Bene Israel, the results of a widely publicised study conducted 
among them turned out to be ‘positive’. As many of my Bene Israel informants 
observed, this did not change anything in their self-perception; yet the results 
could nevertheless be used to counteract the arguments of those who doubted 
the community’s origin narrative (Parfitt and Egorova 2006: 116). When I visited 
the Bene Israel seven years after the tests were conducted, a number of 
respondents stated their satisfaction that the community had undergone the 
tests and that it was now proven once and for all that the Bene Israel were 
Jewish. Thus, paradoxically, DNA testing conducted among Judaising movements 
in different parts of the world, which, to use Sommer’s phrase, many 
commentators would unmistakably identify as ‘part of backward-looking 
socialities’, has acquired a strong reputation as a social liberation tool.    
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For the Indian government, which funded the IGV initiative, it is the 
humiliations of the sub-continent’s colonial past that it is striving to overcome 
through developing biotechnology. As Aditya Bharadwaj has put it, ‘India is 
rapidly challenging its established global image as a provider of call centres, 
cheap technical labour and information technology products, by aggressively 
colonizing the unlikely global site of biotechnology research and innovation’ 
(2009: 6). As was shown above, the participants of the IGV Consortium desire to 
promote through their work an image of India as a locale for competitive and 
innovative R&D. In doing so they strive not just to present the Project’s 
achievements in high-profile journals published in the West, but to involve 
traditional Indian medicine and to ensure that their findings eventually lead to 
an improved health-care system locally.  
At the same time, the usage of biotechnology in the two cases both 
illuminates and reinforces global relations of social and political inequality, in 
addition to well-worn stereotypes about the alleged ‘biological’ differences 
between populations. Using DNA to prove a community’s Jewishness re-inscribes 
notions about ‘Jewish difference’, which emerged in nineteenth century 
European anti-Semitic discourse.16 Studies in human population genetics in 
India, similarly, reinforce the idea that different caste, regional and linguistic 
groups of the subcontinent are biologically distinct.  
I therefore suggest that the examples considered here portray a nuanced 
and complex picture of the social implications of DNA technology. Far from being 
seen purely as a mechanism of neo-colonial oppression, it is being actively used 
not just by the Indian government to advance the development of biotechnology 
in the country, but is also called upon by a community of Dalits who are likely to 
have very little control over the results of a genetic study that could potentially 
be conducted among them. In the first case considered in the paper, the 
perceived empowering aspect of biotechnology stems from the fact that every 
person, irrespective of her social and economic profile, possesses DNA and can 
produce it ‘on demand’. The inherently reductionist nature of DNA testing is thus 
construed here as liberating. In the second case, the Indian government has 
funded an exercise to map and categorise the genetic profile of its populations. 
The exercise promises to empower the Indian people through securing India’s 
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‘genomic sovereignty’ (Benjamin 2009, Egorova 2010), but it also strives to 
make them more ‘bioavailable’ for Western consumption.  
It is noteworthy that both projects are of course vastly different both in 
scale and in terms of their power to actualize the claims that they make. In the 
case of the Bene Ephraim, their claims to a different status in the local hierarchy 
depend on a wide range of actors  - from their immediate neighbours to local and 
national authorities. As David Moss observes in his study of Christian Dalits of 
Tamil Nadu, different initiatives of Dalit self-empowerment do not automatically 
bring changes in the way these communities are viewed or treated in Indian 
society. As he put it, such ‘redefinition of identity’ ‘is dependent upon the 
unlikely recognition of dominant castes’ (2010: 255). Moreover, in the case of the 
Bene Ephraim, the recognition of their claim to a connection to the Jewish people 
and to their right to immigrate to the State of Israel also depends on Israeli 
authorities. 17  
The case of the IGVC is obviously rather different. This project in 
establishing India’s ‘genomic sovereignty’ is funded by the government of India 
itself, who therefore by implication can be seen as a participant in the project’s  
design and implementation. On many levels, India’s government is bound to have 
more control over such a study than the Bene Ephraim would have over their 
suggested DNA tests. And yet, the IGV initiative shares one important feature 
with our first ethnographic example. Like in the case of the Bene Ephraim, here, 
the empowering aspects of genetic testing have a rhetorical dimension.18 The 
posited value of the genetic mapping that the IGV initiative had set out to 
produce is still highly speculative and the promise of more efficient clinical trials 
is used by IGVC as a rhetorical tool. 19  Just like the leaders of the Bene Ephraim 
hope that DNA tests will bring relevant home and overseas commentators to 
recognizing the community’s new status, IGVC representatives can only hope 
that a predictive population database will eventually help India enhance her 
image of a serious player on the international arena of cutting-edge 
biotechnology research, but at least at this moment in time, they cannot be sure 
of this outcome. The Bene Ephraim leaders cannot possibly know what results 
DNA tests would have for them, but they already conceptualise these tests as a 
potential pathway to recognition and liberation. Similarly, no matter whether the 
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genetic mapping exercise will indeed make the process of conducting clinical 
trials in India more expedient, the very rhetoric of clinical trials merged with the 
rhetoric of DNA research in the discourse of IGV participants constitutes IGV 
initiative as a necessary step in the direction of enriching India’s scientific 
capacitty. In both cases, the empowering and disempowering elements of DNA 
testing appear to co-constitute and co-produce each other, a phenomenon which 
demands greater attention be paid to the context-dependent nature of power 
distribution processes in the application of biotechnologies.       
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